Evofem Biosciences Announces Uplisting to OTCQB
SAN DIEGO, Oct. 3, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) announced today that the trading of its common shares has been upgraded to the OTCQB Venture Market from the OTC Pink Open Market. The Company's ticker symbol remains the same.
The women's health focused biotech company developed and commercializes Phexxi® (lactic acid, citric acid, potassium bitartrate), the first and only FDA-approved hormone-free, contraceptive vaginal gel.
Phexxi net sales have increased for three consecutive quarters; the Company expects that third quarter results, due in mid-November, will continue this trend. Net product sales of the hormone-free contraceptive had already surpassed 2021 levels in the first half of 2022.
Evofem is on track to report top-line data in mid-October 2022 from its registrational Phase 3 clinical trial evaluating Phexxi for the prevention of chlamydia and gonorrhea in women. Positive study outcomes would enable regulatory submissions and potential approval for these potential new indications in 2023. If approved by the FDA, Phexxi will be the first woman-controlled prescription prophylactic against chlamydia and gonorrhea, which are a significant and growing public health concern.
Preliminary CDC data for 2021 show that infections with chlamydia and gonorrhea continued to increase during the second year of the COVID-19 pandemic, with no signs of slowing.
The OTCQB Venture Market provides investors an exchange-comparable information experience with convenient trading through their preferred broker or financial advisor. Listed companies are current in their reporting and undergo an annual verification and management certification process. Investors can find Real-Time quotes and market information at www.otcmarkets.com.
About Evofem Biosciences
Phexxi® is a registered trademark of Evofem Biosciences, Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/evofem-biosciences-announces-uplisting-to-otcqb-301638371.html
SOURCE Evofem Biosciences, Inc.
Company Codes: OTC-BB:EVFM, OTC-PINK:EVFM, OTC-QB:EVFM
© 2022 PR Newswire. All Rights Reserved.